Profil de l'entreprise pour CinCor Pharma, Inc. Action
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Analyse IA de CinCor Pharma, Inc.
Cliquez sur l’une des analyses ci-dessous pour obtenir des informations instantanées de l’IA via finAgent
Dernières analyses d’IA sur CinCor Pharma, Inc.
Aucun fil IA disponible pour cette entreprise pour le moment.